Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. This protein is expressed in human epidermis and endothelial cells and it has a role in cellular proliferation, migration, angiogenesis and adhesion. Multiple transcript variants encoding distinct isoforms have been identified for this gene.[2]
References
↑Kolb C, Mauch S, Peter HH, Krawinkel U, Sedlacek R (Oct 1997). "The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient". Immunol Lett. 57 (1–3): 83–8. doi:10.1016/S0165-2478(97)00057-6. PMID9232430.
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Cossins J, Dudgeon TJ, Catlin G, et al. (1996). "Identification of MMP-18, a putative novel human matrix metalloproteinase". Biochem. Biophys. Res. Commun. 228 (2): 494–8. doi:10.1006/bbrc.1996.1688. PMID8920941.
Pendás AM, Knäuper V, Puente XS, et al. (1997). "Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution". J. Biol. Chem. 272 (7): 4281–6. doi:10.1074/jbc.272.7.4281. PMID9020145.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Sedlacek R, Mauch S, Kolb B, et al. (1998). "Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis". Immunobiology. 198 (4): 408–23. doi:10.1016/s0171-2985(98)80049-1. PMID9562866.
Fosang AJ, Last K, Fujii Y, et al. (1998). "Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain". FEBS Lett. 430 (3): 186–90. doi:10.1016/S0014-5793(98)00667-X. PMID9688535.
Stracke JO, Hutton M, Stewart M, et al. (2000). "Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme". J. Biol. Chem. 275 (20): 14809–16. doi:10.1074/jbc.275.20.14809. PMID10809722.
Stracke JO, Fosang AJ, Last K, et al. (2000). "Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP)". FEBS Lett. 478 (1–2): 52–6. doi:10.1016/S0014-5793(00)01819-6. PMID10922468.
Terp GE, Christensen IT, Jørgensen FS (2000). "Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes". J. Biomol. Struct. Dyn. 17 (6): 933–46. doi:10.1080/07391102.2000.10506582. PMID10949161.
Mauch S, Kolb C, Kolb B, et al. (2002). "Matrix metalloproteinase-19 is expressed in myeloid cells in an adhesion-dependent manner and associates with the cell surface". J. Immunol. 168 (3): 1244–51. doi:10.4049/jimmunol.168.3.1244. PMID11801661.
Rodríguez-Manzaneque JC, Westling J, Thai SN, et al. (2002). "ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors". Biochem. Biophys. Res. Commun. 293 (1): 501–8. doi:10.1016/S0006-291X(02)00254-1. PMID12054629.
Titz B, Dietrich S, Sadowski T, Beck C, Petersen A, Sedlacek R (2004). "Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1". Cell Mol Life Sci. 61 (14): 1826–33. doi:10.1007/s00018-004-4105-0. PMID15241558.
External links
The MEROPS online database for peptidases and their inhibitors: M10.021
